What Fueled The Previous Growth In The Artificial Intelligence AI In Respiratory Diseases Market?
The artificial intelligence ai in respiratory diseases market has seen considerable growth due to a variety of factors.
• The market size of artificial intelligence (AI) in the sector of respiratory diseases has seen significant growth in the past few years. The market was valued at $7.66 billion in 2024 and is projected to increase to $8.05 billion in 2025, resulting in a compound annual growth rate (CAGR) of 5.1%.
Factors contributing to this growth during the historic period include stringency of government regulations, heightened environmental concerns, a rapidly aging population, a shift towards patient-focused healthcare methods, and an upswing in the development of healthcare infrastructure.
What Is The Expected Growth In The Artificial Intelligence AI In Respiratory Diseases Market Size Evolve over the Forecast Period?
The artificial intelligence ai in respiratory diseases market is expected to maintain its strong growth trajectory in upcoming years.
• The artificial intelligence (AI) market for respiratory diseases is projected to experience robust growth in the upcoming years, reaching a size of $9.85 billion in 2029, with a compound annual growth rate (CAGR) of 5.2%.
This growth trajectory during the prediction period can be linked to a rise in the occurrence of respiratory illnesses, the urgent need for early detection and diagnosis, elevated levels of environmental pollution, increased healthcare spending, and research and development efforts. Key trends for the forecast period encompass technological progression, advancements in drug discovery and development, tailor-made treatment plans, the use of telemedicine and remote patient monitoring.
What Main Forces Are Fueling Expansion In The Artificial Intelligence AI In Respiratory Diseases Market?
The escalating issue of environmental contamination is projected to fuel the expansion of the artificial intelligence (AI) sector in the respiratory disease market. The term environmental pollution is used to describe the rapid influx of unwanted substances or energy forms into the environment that surpasses its diffusion or storage capacity in a harmless way. AI can significantly mitigate the detrimental effects of environmental pollution on respiratory health by providing real-time surveillance, customized risk evaluations, knowledge-based decision-making, and pioneering resolutions for both individuals and societies. For example, data from the US Energy Information Administration, a government agency in the United States, reveals that the CO2 emissions in 2021 were 35.72 billion metric tons, and they increased to 38.50 billion metric tons in 2022. Consequently, the increasing environmental pollution is stimulating the expansion of AI in the respiratory disease market.
What Are The Primary Segments In The Global Artificial Intelligence AI In Respiratory Diseases Market?
The artificial intelligence (AI) in respiratory diseases market covered in this report is segmented –
1) By Imaging Type: Magnetic Resonance Imaging (MRI), Computed Tomography (CT) Scan, Electronic Patient-Reported Outcomes (ePRO)
2) By Indication: Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease, Pulmonary Infection
3) By End Use: Hospital, Diagnostic Centers, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Magnetic Resonance Imaging (MRI): Lung Imaging, Thoracic Imaging, Cardiopulmonary Imaging
2) By Computed Tomography (CT) Scan: High-Resolution CT (HRCT), Low-Dose CT, Thoracic CT
3) By Electronic Patient-Reported Outcomes (ePRO): Symptom Tracking, Medication Adherence Monitoring, Quality Of Life Assessments
Pre-Book The Artificial Intelligence AI In Respiratory Diseases Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Artificial Intelligence AI In Respiratory Diseases Market?
Prominent firms in the artificial intelligence (AI) field within the respiratory diseases market are pioneering for the creation of ground-breaking products such as N-Tidal devices, which are used to track the tidal breathing of patients. These devices evaluate the volume of air replaced during regular breathing which gives critical data about the functioning of the lungs. To illustrate, in August 2023, TidalSense, a respiratory technology firm based in the UK, introduced N-Tidal, a strictly regulated AI technology designed for the diagnosis and management of chronic obstructive pulmonary disease (COPD). This technology integrates CO2 sensor data from N-Tidal with an AI platform, creating a system designed to measure alterations in lung function with the ambition to enhance the diagnosis and management of this particular respiratory condition. Clinical research has shown superior accuracy of this technology, paving way for radical changes in the diagnostic procedure for respiratory diseases. The advent of this technology is a key development in the application of AI in assessing respiratory diseases, offering an easier and more resourceful substitute to existing diagnostic procedures.
Who Are the Key Players In The Artificial Intelligence AI In Respiratory Diseases Market?
Major companies operating in the artificial intelligence (AI) in respiratory diseases market report are:
• Siemens Healthineers
• Philips Healthcare
• General Electric (GE) Healthcare
• Verily Life Sciences LLC
• DeepMind Health
• Merative L.P.
• Innovaccer
• Freenome
• Aidoc Medical
• Butterfly Network
• Infervision
• Imagen Technologies
• Caption Health
• Gauss Surgical Inc.
• Swaasa AI
• Inspirata Inc.
• VIDA Diagnostics Inc.
• Enlitic
• Thirona B.v.
• ArtiQ
• Icometrix
• Zynnon AG
• Aidence
• Arterys
• Dectrocel Healthcare
• PneumoWave Ltd.
What Is The Most Dominant Region In The Artificial Intelligence AI In Respiratory Diseases Market?
North America was the largest region in the artificial Intelligence (AI) in respiratory diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) in respiratory diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
